170 related articles for article (PubMed ID: 37030295)
1. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.
Perurena N; Lock R; Davis RA; Raghavan S; Pilla NF; Ng R; Loi P; Guild CJ; Miller AL; Sicinska E; Cleary JM; Rubinson DA; Wolpin BM; Gray NS; Santagata S; Hahn WC; Morton JP; Sansom OJ; Aguirre AJ; Cichowski K
Cell Rep Med; 2023 Apr; 4(4):101007. PubMed ID: 37030295
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
[TBL] [Abstract][Full Text] [Related]
3. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma.
Cox JL; Wilder PJ; Wuebben EL; Ouellette MM; Hollingsworth MA; Rizzino A
Cancer Biol Ther; 2014 Aug; 15(8):1042-52. PubMed ID: 24841553
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitylating enzyme USP9x regulates radiosensitivity in glioblastoma cells by Mcl-1-dependent and -independent mechanisms.
Wolfsperger F; Hogh-Binder SA; Schittenhelm J; Psaras T; Ritter V; Bornes L; Huber SM; Jendrossek V; Rudner J
Cell Death Dis; 2016 Jan; 7(1):e2039. PubMed ID: 26775694
[TBL] [Abstract][Full Text] [Related]
5. Elevated USP9X drives early-to-late-stage oral tumorigenesis via stabilisation of anti-apoptotic MCL-1 protein and impacts outcome in oral cancers.
Sulkshane P; Pawar SN; Waghole R; Pawar SS; Rajput P; Uthale A; Oak S; Kalkar P; Wani H; Patil R; Nair S; Rane P; Teni T
Br J Cancer; 2021 Aug; 125(4):547-560. PubMed ID: 34079080
[TBL] [Abstract][Full Text] [Related]
6. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.
Brown WS; McDonald PC; Nemirovsky O; Awrey S; Chafe SC; Schaeffer DF; Li J; Renouf DJ; Stanger BZ; Dedhar S
Cell Rep Med; 2020 Nov; 1(8):100131. PubMed ID: 33294856
[TBL] [Abstract][Full Text] [Related]
7. Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells.
Yan J; Zhong N; Liu G; Chen K; Liu X; Su L; Singhal S
Cell Death Dis; 2014 Jul; 5(7):e1316. PubMed ID: 24991768
[TBL] [Abstract][Full Text] [Related]
8. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.
Peterson LF; Sun H; Liu Y; Potu H; Kandarpa M; Ermann M; Courtney SM; Young M; Showalter HD; Sun D; Jakubowiak A; Malek SN; Talpaz M; Donato NJ
Blood; 2015 Jun; 125(23):3588-97. PubMed ID: 25814533
[TBL] [Abstract][Full Text] [Related]
9. Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers.
Li B; Feng Y; Hou Q; Fu Y; Luo Y
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806187
[TBL] [Abstract][Full Text] [Related]
10. Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth.
Pal A; Dziubinski M; Di Magliano MP; Simeone DM; Owens S; Thomas D; Peterson L; Potu H; Talpaz M; Donato NJ
Neoplasia; 2018 Feb; 20(2):152-164. PubMed ID: 29248719
[TBL] [Abstract][Full Text] [Related]
11. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.
Pérez-Mancera PA; Rust AG; van der Weyden L; Kristiansen G; Li A; Sarver AL; Silverstein KA; Grützmann R; Aust D; Rümmele P; Knösel T; Herd C; Stemple DL; Kettleborough R; Brosnan JA; Li A; Morgan R; Knight S; Yu J; Stegeman S; Collier LS; ten Hoeve JJ; de Ridder J; Klein AP; Goggins M; Hruban RH; Chang DK; Biankin AV; Grimmond SM; ; Wessels LF; Wood SA; Iacobuzio-Donahue CA; Pilarsky C; Largaespada DA; Adams DJ; Tuveson DA
Nature; 2012 Apr; 486(7402):266-70. PubMed ID: 22699621
[TBL] [Abstract][Full Text] [Related]
12. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
[TBL] [Abstract][Full Text] [Related]
13. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
14. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1.
Trivigno D; Essmann F; Huber SM; Rudner J
Neoplasia; 2012 Oct; 14(10):893-904. PubMed ID: 23097624
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.
Diehl JN; Hibshman PS; Ozkan-Dagliyan I; Goodwin CM; Howard SV; Cox AD; Der CJ
Adv Cancer Res; 2022; 153():101-130. PubMed ID: 35101228
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
Akiyama H; Umezawa Y; Ishida S; Okada K; Nogami A; Miura O
Cancer Lett; 2019 Jul; 453():84-94. PubMed ID: 30946869
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinase USP9X promotes cell migration, invasion and inhibits apoptosis of human pancreatic cancer.
Liu L; Yao D; Zhang P; Ding W; Zhang X; Zhang C; Gong S; Zhang Y; Wang J; Sun T; Ren Z
Oncol Rep; 2017 Dec; 38(6):3531-3537. PubMed ID: 29130109
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation.
Godfrey LK; Forster J; Liffers ST; Schröder C; Köster J; Henschel L; Ludwig KU; Lähnemann D; Trajkovic-Arsic M; Behrens D; Scarpa A; Lawlor RT; Witzke KE; Sitek B; Johnsen SA; Rahmann S; Horsthemke B; Zeschnigk M; Siveke JT
Clin Epigenetics; 2024 Jan; 16(1):13. PubMed ID: 38229153
[TBL] [Abstract][Full Text] [Related]
19. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.
Peddaboina C; Jupiter D; Fletcher S; Yap JL; Rai A; Tobin RP; Jiang W; Rascoe P; Rogers MK; Smythe WR; Cao X
BMC Cancer; 2012 Nov; 12():541. PubMed ID: 23171055
[TBL] [Abstract][Full Text] [Related]
20. Anticipating resistance to KRAS inhibition: a novel role for USP21 in macropinocytosis regulation.
Crawford HC
Genes Dev; 2021 Oct; 35(19-20):1325-1326. PubMed ID: 34599002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]